Picture of Moberg Pharma AB (publ) logo

MOB Moberg Pharma AB (publ) Share Price

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m+37.03%
3m+59.22%
6m+192.4%
1yr+8.79%
Volume Change (%)
10d/3m+27.81%
Price vs... (%)
52w High-4.17%
50d MA+35.04%
200d MA+110.02%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-4.47%
Return on Equity-3.69%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Moberg Pharma AB (publ) EPS forecast chart

Profile Summary

Moberg Pharma AB is a Sweden-based pharmaceutical company. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The Company collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. It is active in more than 35 countries, and operates, among others, through Alterna LLC. It also owns three Over-The-Counter (OTC) brands in the United States.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
January 31st, 2006
Public Since
May 26th, 2011
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
se flag iconOMX Nordic Exchange Stockholm
Shares in Issue
27,961,478

MOB Share Price Performance

Upcoming Events for MOB

Q1 2024 Moberg Pharma AB (publ) Earnings Release

Moberg Pharma AB (publ) Annual Shareholders Meeting

Q2 2024 Moberg Pharma AB (publ) Earnings Release

Similar to MOB

Picture of Biogaia AB logo

Biogaia AB

se flag iconOMX Nordic Exchange Stockholm

Picture of BoneSupport Holding AB logo

BoneSupport Holding AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Calliditas Therapeutics AB logo

Calliditas Therapeutics AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Camurus AB logo

Camurus AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Cline Scientific AB logo

Cline Scientific AB

se flag iconOMX Nordic Exchange Stockholm

FAQ